AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference

AlzeCure Pharma announced that an abstract on ACD440, the leading non-opioid drug candidate in the Painless platform, has been accepted for presentation at the annual pain conference to be held by the Swedish Pain Society in Uppsala, Sweden, on October 12-13.